Yahoo Finance Pleasing Signs As A Number Of Insiders Buy Aprea Therapeutics Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Aprea Therapeutics, Inc. (NASDAQ:APRE), that sends out a positive message to the company's shareholders.
While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.
See our latest analysis for Aprea Therapeutics
Aprea Therapeutics Insider Transactions Over The Last Year
The Independent Director John Henneman made the biggest insider purchase in the last 12 months. That single transaction was for US$50k worth of shares at a price of US$7.29 each. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$4.41). It's very possible they regret the purchase, but it's more likely they are bullish about the company. In our view, the price an insider pays for shares is very important. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.
Aprea Therapeutics insiders may have bought shares in the last year, but they didn't sell any. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Aprea Therapeutics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
Aprea Therapeutics Insiders Bought Stock Recently
Over the last quarter, Aprea Therapeutics insiders have spent a meaningful amount on shares. Overall, four insiders shelled out US$122k for shares in the company -- and none sold. This makes one think the business has some good points.
Insider Ownership Of Aprea Therapeutics
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that Aprea Therapeutics insiders own 11% of the company, worth about US$2.6m. We do generally prefer see higher levels of insider ownership.
What Might The Insider Transactions At Aprea Therapeutics Tell Us?
It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Aprea Therapeutics insiders are expecting a bright future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Our analysis shows 5 warning signs for Aprea Therapeutics (1 is a bit unpleasant!) and we strongly recommend you look at these before investing.
Of course Aprea Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
